Rivastigmine

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Retrieved on: 
Thursday, November 9, 2023
Alzheimer's disease, PubMed, Rivastigmine, Brain, OTCQB, Food, Ageing, Memantine, Disease, Alzheimer's Disease International, FDA, ADI, Dementia, NIH, AMD, Alzheimer's Association, Macular degeneration, Donepezil, United States patent law, Bangladesh Technical Education Board, Galantamine, Injection, Life, Pharmaceutical industry

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.

Key Points: 
  • PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
  • There are two forms of the disease; wet AMD and dry AMD.
  • ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
  • The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)

Retrieved on: 
Friday, April 28, 2023
Cognition, CSE, Traumatic brain injury, LE, Memantine, Rivastigmine, Disclosure, Donepezil, Patient, Concussion, Cognitive deficit, Pharmaceutical industry, Department store

Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.
  • Listing and disclosure documents will be available at www.thecse.com on the trading date.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
  • Les actions ordinaires et les bons de souscription d'Alpha Cognition Inc. ont été approuvés pour inscription à la CSE.

Global Alzheimer's Disease Therapeutics Market Research Report 2023: A $7.16 Billion Market by 2028 - 150+ Assets in Various Development Phases - Epidemiology & Pipeline Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 28, 2023
Pharmaceutical, Health, Neurology, Magnetic resonance imaging, USFDA, Galantamine, Dementia, Therapy, MAA, Geography, Biogen, Eli Lilly and Company, Safety, Rivastigmine, Magnetism, Deficit spending, Research, Patient, MRI, Neurodegenerative disease, Sleep, AD, Central nervous system, Computerize, Food, Phase, Knowledge, Marketing Authorisation Application, Moa, Enzyme inhibitor, Investment, CT, Growth, PET, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Prevalence, Cassava Sciences, Clinical trial, Memantine, European Medicines Agency, FDA, NMDA, Amnesia, Forgetting, EMA, Pharmaceutical industry, Medicinal plants, Medical imaging, Alzheimer's disease, Donepezil, Epidemiology, Aducanumab

The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.

Key Points: 
  • The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.
  • The Alzheimer's disease therapeutics market portfolio contains a total of 151+ assets in various development phases.
  • The Alzheimer's disease therapeutics market has been witnessing considerable growth, which is attributed to the increasing prevalence of Alzheimer's Disease worldwide.
  • The global Alzheimer's disease therapeutics market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Alzheimer's Disease.

The Worldwide Alzheimer's Drugs Industry is Expected to Reach $7.48 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023
Health, Pharmaceutical, Brain, Dementia, Government, Insight, Abbott Laboratories, Myenteric plexus, Investment, World Health Organization, AC, Novartis, Eli Lilly and Company, Teva Pharmaceuticals, Medicare, Patient, Clifton Springs Hospital & Clinic, Pfizer, Research, GSK plc, Merck & Co., Boehringer Ingelheim, Texas Homecare, USD, Research report, WHO, World Ag Expo, Alzheimer's Association, Disease, US, Morphome (linguistics), Conditional sentence, Memantine, Nursing home, Ageing, Dietary supplement, Residential care, Pharmaceutical industry, Medicinal plants, Alzheimer's disease, Donepezil, Bayer, Rivastigmine, Growth, Galantamine, Hospital

The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.

Key Points: 
  • The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.
  • Instead, the disease is caused by genetic, lifestyle, and environmental components that influence the brain over time.
  • According to the World Health Organization (WHO), Alzheimer's disease contributes to 60%-70% of dementia cases.
  • As per this research report, Globally Alzheimer's Drugs Market was valued at US$ 5.16 Billion in 2022.

Insights on the Alzheimer's Drugs Global Market to 2027 - Hospital Sector will Capture more Revenue in Upcoming Years

Retrieved on: 
Wednesday, January 25, 2023
Conditional sentence, Research report, USD, Dementia, Insight, Texas Homecare, GSK plc, Merck & Co., Boehringer Ingelheim, Teva Pharmaceuticals, Medicare, Novartis, Morphome (linguistics), Pfizer, Government, AC, Nursing home, World Ag Expo, US, Eli Lilly and Company, Brain, Memantine, Ageing, Abbott Laboratories, World Health Organization, Patient, WHO, Disease, Clifton Springs Hospital & Clinic, Myenteric plexus, Investment, Research, Alzheimer's Association, Residential care, Pharmaceutical industry, Medicinal plants, Rivastigmine, Donepezil, Galantamine, Growth, Alzheimer's disease, Hospital, Bayer

The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.

Key Points: 
  • The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.
  • Based on Drug class, the Alzheimer's disease drug market is segmented into; Donepezil, Galantamine, Rivastigmine, Memantine, and Others.
  • The hospital segment dominated the market share, owing to the growth in the hospitalization of the older population and Alzheimer's patients.
  • Based on region, the Alzheimer's disease market is divided into; North America, Europe, Asia-Pacific, and the Rest of the World.

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, COVID-19, Tablet, Growth, Traumatic brain injury, Donepezil, TSX, OTC Markets Group, Food, Rivastigmine, G&A, Cognition, R, TSX Venture Exchange, Acquisition, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, USD, Alzheimer's disease, Net, Toxicity, Research, Inflammation, Capsule, Central nervous system, Disease, Amyotrophic lateral sclerosis, News, Neurodegeneration, NDA, ACOG, ALS, Growth hacking, Failure, Depreciation, Memantine, Survival, Advertising, FDA, Pharmaceutical industry, Cryptocurrency, Aluminium

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the third quarter ended September 30, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the third quarter ended September 30, 2022.
  • The goal of this meeting is to align with the FDA on the next steps for this important clinical program.
  • Traumatic brain injury is a condition which affects millions of people each year yet has no approved therapy.
  • The Company announced that it has withdrawn the marketed public offering of units previously announced on November 17, 2022.

Alpha Cognition Announces Marketed Offering

Retrieved on: 
Thursday, November 17, 2022
Marketing, Donepezil, Rivastigmine, Cognition, TSX Venture Exchange, Agent, Patient, Issue, Toxicity, Inflammation, Central nervous system, Disease, Amyotrophic lateral sclerosis, SEDAR, Indian stock exchange, Neurodegeneration, Sale, ACOG, Alzheimer's disease, ALS, Growth hacking, Gemstone, Offering, Memantine, Survival, FDA, Pharmaceutical industry, Security (finance), Unit

VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced a marketed public offering (the “Offering”) of units (the “Units”) for up to $10 million.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (Alpha or the Company) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced a marketed public offering (the Offering) of units (the Units) for up to $10 million.
  • The Company will also grant the Agents an option (the Over-Allotment Option) to sell up to an additional 15% of the Units sold under the Offering, at the Issue Price.
  • The Offering will be conducted pursuant to the Companys Canadian base shelf prospectus dated February 24, 2022 (the Base Shelf Prospectus).
  • A prospectus supplement (the Prospectus Supplement) relating to the Offering will be filed in each of the provinces of Canada, except the Province of Quebec.

Alzheimers Therapeutic Global Market Report 2022: Featuring Pfizer, Novartis, AstraZeneca, Eli Lilly, Merck, Acadia & More - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Biotechnology, Pharmaceutical, Health, Disease, Therapy, Amnesia, Thought, Insulin resistance, Confusion, Patient, Galantamine, Research, Rivastigmine, Inflammation, Donepezil, Memantine, Association, Alzheimer's Association, Medicinal plants, Pharmaceutical industry, Alzheimer's disease

The "Alzheimers Therapeutic Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimers Therapeutic Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report on global Alzheimer's therapeutics market studies various drugs used for the treatment of Alzheimer's along with pipeline analysis of upcoming potential drugs.
  • The pipeline analysis for Alzheimer's therapeutics market comprises projected market sales of Phase III drugs estimated till 2022.
  • According to medical practitioners, donepezil, rivastigmine or galantamine is offered as part of treatment for patients with mild-to-moderate Alzheimer's disease.

North America Alzheimer's Disease Therapeutics and Diagnostics Market 2022-2028: Lucrative Opportunities in the Emergence of New Diagnostic Technologies & Growing Number of Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Biotechnology, Pharmaceutical, Health, US Census Bureau International Data Base, Food and Drug Administration, NIH, NCT, Growth, United States Census Bureau, Therapy, Ageing, Donepezil, Memantine, AD, Galantamine, National, Rivastigmine, Population, Pharmaceutical industry, Alzheimer's disease

The "North America Alzheimer'S Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Alzheimer'S Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The United States accounts for the leading share in the AD therapeutics and diagnostics market.
  • Data from the National Institutes of Health (NIH) suggests that, nearly 5.8 million Americans were affected by Alzheimer's disease as of 2020.
  • This will enhance the demand for therapeutics and diagnostics for AD, and thus contribute to the growth of the US market.

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, August 25, 2022
Biotechnology, Pharmaceutical, Health, Neurology, Inflammation, Partnership, COVID-19, TBI, NDA, Tablet, Research, Technology, Second, Survival, Amyotrophic lateral sclerosis, Central nervous system, Spinal muscular atrophy, Cognition, Toxicity, Disease, Burn, R, Gemstone, USD, Depreciation, Advertising, ACOG, TSX, Alzheimer's disease, Growth hacking, Rivastigmine, OTC Markets Group, Neurodegeneration, Donepezil, Company, FDA, Memantine, Met, News, Failure, Transaction, TSX Venture Exchange, Terminology, Potential, Growth, Industry, Discovery, Acquisition, Capsule, ALS, Patient, P-value, Income, Pharmaceutical industry, Renewable energy, Medical device, Dietary supplement, Online gambling, Cryptocurrency, Tutoring, G&A

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.
  • "The Company released positive topline data from the ALPHA-1062 pivotal trial during the second quarter of 2022 which allows for the preparation of an NDA filing for the product.
  • The Company is seeking additional capital to fund this study initiation and will commence the study within a quarter to securing the required funding.
  • R&D expenses increased in 2022 primarily due to the additional costs associated with advancing ALPHA-1062 and ALPHA-0602 clinical and preclinical studies.